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In ENOS, one of the largest randomised trials of blood 
pressure-lowering in acute stroke now published in 
The Lancet, Philip Bath and colleagues1 assessed whether 
blood pressure could be safely lowered with a daily 
glyceryl nitrate patch for 7 days after acute stroke, and 
whether antihypertensive drugs should be continued or 
withdrawn. Blood pressure is increased in about 70% of 
patients with acute stroke and often falls spontaneously 
over the next few days.2 The potential causes of this 
transient rise include disturbed cerebral autoregulation, 
damage or compression of brain regions that regulate 
blood pressure, neuroendocrine disturbance, and non-
speciﬁ c mechanisms such as headache, urine retention, 
infection, and psychological stress.2,3 There is also 
evidence, particularly in patients with intracerebral 
haemorrhage, that high post-stroke blood pressure 
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in patients with the atypical form of this disorder than in 
those with the typical form,4 although fertility outcomes 
might be attributable to unidentiﬁ ed factors associated 
with the transplant procedure itself. The accompanying 
case1 therefore emphasises the importance of recipient 
selection, not only for the purposes of the transplant 
but also for assisted reproductive procedures so that the 
recipient will obtain suﬃ  cient numbers of oocytes and 
embryos before transplantation. It also provokes key 
ethical questions about the need for guidance regarding 
balancing of the risks and beneﬁ ts of ovarian stimulation 
and oocyte retrieval eﬀ orts to increase the number of 
transferable embryos before transplant, the possibility 
of using donor gametes and embryos in cases where the 
recipient’s supply of embryos is exhausted, and the need 
for ongoing research to clarify safety and protocols to 
undertake in-vitro fertilisation in women post-transplant.
Another key set of complications exists, the occurrence 
and severity of which could only be speculated upon until 
recently. The transplant recipient in the report1 developed 
pre-eclampsia and preterm contractions at 31 weeks and 
5 days, and subsequently required steroids and preterm 
delivery by caesarean section. Whether these obstetric 
complications were due to the age of the donor, issues 
related to single kidney function, immunosuppression, 
or other factors is not yet clear. Moreover, although 
a livebirth following uterine transplant is a notable 
success, the eﬀ ect of prematurity on the infant cannot 
be underestimated. In this case, the neonate needed 
only minimum support following delivery. However, 
the sequelae of prematurity are well documented.5 
Therefore, additional research will be necessary to 
establish whether the obstetric complications described 
in the report represent a set of events that will recur in 
all transplant recipients. Such data will only be obtained 
from observations on other women who elect to undergo 
uterine transplant and pregnancy.
Finally, although Brännström and colleagues state1 that 
they plan to remove the transplanted uterus to reduce 
the long-term risks of ongoing immunosuppression for 
the recipient, the decision to remove the uterus must 
be an informed and voluntary decision by the recipient. 
Although the recipient’s partner might have input into 
her decision making, the choice to undergo further 
surgery with resultant removal of reproductive function 
can only be made by the recipient herself.
The successful birth of a child following a uterus 
transplant provokes a series of medical and ethical 
challenges, the breadth and depth of which have not 
yet been explored in the context of other transplanted 
organs. The unique aspects of uterine transplantation 
will need ongoing multidisciplinary analysis of the 
lead clinical and ethical issues for the donor, recipient, 
oﬀ spring, and other key stakeholders involved in this 
innovative family-building procedure.
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might be due to an increase in the hours or days before 
the event.4
Observational data have consistently shown that high 
blood pressure after acute stroke is associated with poor 
outcomes.5 Raised blood pressure might increase cerebral 
oedema or haemorrhagic transformation in ischaemic 
stroke, or lead to haematoma expansion and rebleeding 
in intracerebral haemorrhage, but lowering of blood 
pressure might reduce cerebral blood ﬂ ow and increase 
infarction or perihaematomal ischaemia.2 Indeed, some 
small trials of acute blood pressure-lowering after 
ischaemic stroke did suggest increased early mortality 
and worse functional outcome.6 More recently, of the 
two previous largest trials of blood pressure-lowering in 
predominantly acute ischaemic stroke,7,8 one reported 
an increase in stroke progression in patients treated 
with candesartan versus placebo and a worse functional 
outcome,7 and the other reported no reduction in rates of 
death or disability with lowering versus discontinuation 
of any antihypertensive treatment.8 A recent systematic 
review of these and 15 other randomised trials, including 
13 236 participants, showed no eﬀ ect of early blood 
pressure-lowering versus control on functional outcome, 
with some evidence of increased early mortality.6 Practice 
has therefore been to tolerate high blood pressure in 
most patients who are not candidates for thrombolysis, 
although recent evidence that early reduction of high 
blood pressure after intracranial haemorrhage might 
improve outcome is changing clinical management of 
patients with this disorder.9
ENOS1 was a multicentre, randomised, partial-
factorial trial that enrolled patients within 48 h of 
acute ischaemic (83%) or haemorrhagic (16%) stroke 
with systolic blood pressure between 140 mm Hg and 
220 mm Hg. 4011 patients with mean blood pressure of 
167/90 mm Hg were randomly assigned to receive either 
transdermal glyceryl trinitrate 5 mg every day versus a 
matching patch without glyceryl trinitrate (placebo) for 
7 days. Mean blood pressure was 7·0/3·5 mm Hg lower 
in those given glyceryl trinitrate than in those given 
no glyceryl trinitrate on day 1. Although adherence to 
treatment was very high, this diﬀ erence was no longer 
signiﬁ cant by day 3, and there was no diﬀ erence between 
the treatment groups in neurological deterioration, 
recurrent stroke, or death at 7 days, and no diﬀ erence 
in the primary outcome of functional status (change in 
modiﬁ ed Rankin scale score) at 90 days.
Given previous concern about increased early 
progression of acute ischaemic stroke after treatment 
of hypertension, as reported in the SCAST trial (6% on 
candesartan vs 4% on placebo; risk ratio 1·47, 95% CI 
1·01–2·13),7 the absence of adverse eﬀ ects with glyceryl 
trinitrate in ENOS is reassuring. ENOS also showed no 
adverse eﬀ ect of glyceryl trinitrate on functional outcome 
in patients with acute stroke with severe symptomatic 
extracranial carotid stenosis, analogous with previous 
evidence that low blood pressure is only associated with 
an increased risk of recurrent stroke in the small subset of 
patients with bilateral severe stenosis or occlusion.10
The median time from stroke onset to randomisation 
in ENOS was 26 h, which is similar to the delay in 
previous large trials of blood pressure-lowering in acute 
ischaemic stroke.7,8 However, blood pressure is highest 
in the ﬁ rst few minutes after stroke onset,4 at which 
point any adverse pathophysiological eﬀ ects might also 
be greatest. In the 273 (7%) patients recruited to ENOS 
within 6 h of stroke onset, allocation to glyceryl trinitrate 
did improve the primary outcome (OR=0·55, 95% CI 
0·36–0·84). However, although this apparent subgroup–
treatment eﬀ ect interaction was signiﬁ cant, there was no 
evidence of any continuing interaction with increasing 
time beyond 6 h, and a more conservative analysis of the 
four equal 12 h periods would be non-signiﬁ cant. In the 
two previous large trials in acute ischaemic stroke, there 
was also no evidence of beneﬁ t in functional outcome 
in the subgroups randomised earliest.7,8 Nevertheless, it 
remains possible that ENOS has identiﬁ ed a speciﬁ c acute 
eﬀ ect of glyceryl trinitrate, rather than a generic eﬀ ect 
of early blood pressure-lowering, and some supporting 
evidence has been provided by a small previous pilot 
trial of ambulance initiation of glyceryl trinitrate in 
hyperacute stroke.11 A large trial of this intervention by 
Bath and colleagues (the RIGHT-2 trial) is now funded 
and will address this question. 
Investigators for ENOS also randomly assigned 
2097 patients to continue versus stop their existing 
antihypertensive drugs. The only previous trial to have 
addressed this clinically important question did not show 
any harms from continuing drugs,12 but was potentially 
underpowered. In ENOS, whether drugs were continued 
versus stopped had no signiﬁ cant eﬀ ect on the primary 
outcome or on the risk of early deterioration at 7 days, but 
continuation did signiﬁ cantly worsen the Barthel index 
(<60) at 90 days and increased cognitive impairment 
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in the subset of patients tested (1272 of 2095). 
Continuation also increased the risk of pneumonia, 
possibly related to aspiration. Risk of post-stroke 
cognitive impairment is strongly related to severity and 
complications of stroke,13 and so this pattern of outcomes 
is plausible. Thus, although the primary outcome was not 
signiﬁ cantly adversely aﬀ ected by continuation of drugs, 
the authors’ conclusion that withholding blood pressure-
lowering drugs after acute ischaemic stroke until patients 
are neurologically stable and treatment can be given 
safely is reasonable, and clinical guidelines will now need 
to make speciﬁ c recommendations.
ENOS was a very well designed and executed trial, 
and outstanding questions relate mainly to how far the 
results should be generalised. Firstly, ENOS and almost all 
previous similar trials of acute blood pressure-lowering 
either excluded or recruited very few patients with 
transient ischaemic attack and minor stroke, although 
patients with these events now represent more than 
70% of all referrals with acute cerebrovascular events in 
routine practice. Blood pressure-lowering a few days or 
weeks after transient ischaemic attack or minor stroke is 
known to be safe and eﬀ ective to reduce long-term risk 
of major stroke, and early initiation of blood pressure-
lowering drugs is associated with a low risk of recurrent 
stroke.14 Therefore, any conclusions from the results of 
trials of acute blood pressure-lowering in major acute 
stroke should not be generalised to transient ischaemic 
attack and minor stroke.
Secondly, although ENOS included 629 patients 
with intracerebral haemorrhage and showed no 
improvement in functional outcome, consistent with 
the similar subgroup analysis of 274 patients with 
intracerebral haemorrhage in the SCAST trial,7 this 
ﬁ nding does not conﬂ ict with the non-signiﬁ cant 
beneﬁ ts reported in the INTERACT trials in more than 
3000 patients with intracerebral haemorrhage.9 In these 
trials, blood pressure-lowering was started much earlier 
after the onset of stroke (mean time to randomisation 
was about 4 h) and treatment was more aggressive. It 
is hoped that future pooled analyses of data from all of 
these trials might cast further light on the interactions 
between these parameters and the eﬀ ects of treatment 
in intracerebral haemorrhage. Thirdly, there remains 
uncertainty about the optimum early management of 
blood pressure in patients with acute ischaemic stroke 
who are candidates for thrombolysis. It is common 
practice to avoid thrombolysis when systolic blood 
pressure is higher than 185 mm Hg because of an 
increased risk of symptomatic intracranial haemorrhage. 
The continuing ENCHANTED trial (NCT01422616) aims 
to assess whether intensive blood pressure-lowering 
(130–140 mm Hg target) improves outcomes compared 
with the guideline-recommended level of 180 mm Hg 
in patients eligible for thrombolysis in acute ischaemic 
stroke. Finally, there is evidence that variability of 
blood pressure in acute stroke is associated with a poor 
outcome, independently of mean blood pressure.15 
Future analyses of data from ENOS should establish the 
eﬀ ects of glyceryl trinitrate on variability. 
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In hospitals in high-income and middle-income 
countries with universal access to special or intensive 
newborn care, antenatal corticosteroids are routinely 
given to mothers in preterm labour. A systematic 
review1 of 21 randomised trials showed that antenatal 
corticosteroids accelerated fetal lung maturation, 
reduced respiratory distress, and cut neonatal deaths by 
31%. Recently, international agencies have lobbied to 
make antenatal corticosteroids universally accessible to 
cut preterm deaths in poor countries. The authors of Save 
the Children’s State of the World’s Mothers 2013 report2 
concluded that more than one million babies per year 
could be saved with four life-saving products, including 
antenatal corticosteroids, which are ready to be scaled 
up and would “reduce incalculable suﬀ ering”. A WHO 
global report and an analysis for the UN Commission 
on Life-Saving Commodities for Women and Children 
using the LiST tool estimated that up to 400 000 lives 
could be saved each year by antenatal corticosteroids in 
low-resource settings.3,4
We urged extreme caution with this policy, 
fearing that the balance of risks and beneﬁ ts in poor 
populations could be very diﬀ erent from those in well 
nourished, wealthy populations with access to round-
the-clock special newborn care.5 Would mortality of 
preterm infants really fall in the absence of special care, 
and might maternal infection rates rise if steroids were 
widely used? Others responded that “no published data 
suggest a major risk of maternal infection with the use 
of antenatal corticosteroids”,6 and that, contrary to 
our speculation, “antenatal corticosteroids are likely to 
have a greater eﬀ ect [on mortality] in the absence of 
level 2 care, not a lesser eﬀ ect”.7 Critics further noted 
that “a one-oﬀ  course of antenatal corticosteroids 
(<48 h) poses a very low risk of adverse eﬀ ects”,8 that the 
treatment is one of the UN Commission on Life-Saving 
Commodities’ priority medicines for scale-up,9 and that 
“the evidence strongly supports giving a single, short 
course of corticosteroids to women at risk of preterm 
birth in hospitals everywhere, not just in high-income 
countries”.8
The results of Fernando Althabe and colleagues’ 
excellent international, cluster randomised trial10 
of an intervention designed to increase the use of 
antenatal corticosteroid treatment in low-resource 
settings, reported in The Lancet, show that fears 
about the scale-up of antenatal corticosteroids 
were actually underestimated. The study population 
consisted of almost 100 000 pregnant women in 
six countries—Argentina (six clusters), Zambia (ten), 
Guatemala (ten), Belgaum, India (20), Nagpur, India 
(20), Pakistan (20), and Kenya (16). Compared with 
standard care, the use of a multifaceted intervention 
that included training in the identiﬁ cation of women 
at risk of preterm birth and increased use of antenatal 
corticosteroids was associated with an increase 
in overall newborn mortality of 12% (relative risk 
[RR] 1·12, 95% CI 1·02–1·22; p=0·0127), in perinatal 
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